AgingResearch.NewsJoin free

Lumos Pharma

CompanyUnited States

Lumos Pharma develops one asset, in human trials (Ibutamoren in growth hormone deficiency). Mostly small molecule acting on Insulin/IGF-1 signalling and GHSR; based in the United States.

1
Asset
Furthest stage
Human trials
0
Trials
1
Signal

Pipeline

1

  • Ibutamoren

    Activates the ghrelin receptor to increase endogenous pulsatile growth hormone secretion and fat-free mass.

    Human trials, Small molecule, Insulin/IGF-1 signalling, GHSR, growth hormone deficiency, sarcopenia

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms3
  • Signals1
  • Similar companies6

Papers

Intelligence